drugset / Trial / NCT03516630
Effects of Three Single Oral Doses of Trazodone on the QTc Interval Duration in Healthy Volunteers
Phase 1
Completed
20 enrolled
Angelini Pharma
Cross Research S.A. · collabeResearch Technology, Inc. · collab
RandomizedCrossoverDouble-blindOther
Summary
The present study has been designed to evaluate the effect of three doses of trazodone (20, 60 and 140 mg), in comparison to placebo, on the QT/QTc interval of healthy volunteers. Trazodone oral drops 6% formulation has been selected in order to evaluate the three doses using the same formulation, because the lowest available strength for the tablet formulations is 50 mg. According to the E14 guideline on the evaluation of QT/QTc interval prolongation and proarrhythmic potential of antiarrhytmic drugs, a negative control (placebo) and a positive control (moxifloxacin) will also be assessed.
Timeline
- Start
- 2017-03-20
- Primary completion
- 2017-05-01
- Completion
- 2017-05-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Moxifloxacin | Small molecule | 400 mg | Oral |
| Subject | Trazodone | Small molecule | 20 mg | Oral |
| Subject | Trazodone | Small molecule | 60 mg | Oral |
| Subject | Trazodone | Small molecule | 140 mg | Oral |
Indications
No indication recorded.